Arbutus Biopharma Share Price Today
(NASDAQ: ABUS)

Name: Arbutus Biopharma Share Price Today (NASDAQ: ABUS) - Arbutus Biopharma Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Arbutus Biopharma share price is $3.47 & ₹301.78 as on 6 Mar 2025, 2.30 'hrs' IST

$3.47

▲

0.08

(2.36%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Arbutus Biopharma share price in Dollar and Rupees. Guide to invest in Arbutus Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Arbutus Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Arbutus Biopharma share price movements

Today's Low: $3.33
Today's High: $3.47
$3.47
4.18%
Downside
Day's Volatility :4.18%
Upside
0.0%
52 Weeks Low: $2.30
52 Weeks High: $4.73
$3.47
33.72%
Downside
52 Weeks Volatility :51.32%
Upside
26.56%

Arbutus Biopharma (ABUS) Returns

Period	Arbutus Biopharma Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-6.61%	2.1%	0.0%
6 Months	-24.83%	-4.1%	0.0%
1 Year	23.72%	2.2%	0.0%
3 Years	19.79%	11.8%	-11.6%

Arbutus Biopharma (ABUS) Key Statistics

in dollars & INR

Previous Close	$3.39
Open	$3.39
Today's High	$3.47
Today's Low	$3.325
Market Capitalization	$648.1M
Today's Volume	$271.7K
52 Week High	$4.725
52 Week Low	$2.3
Revenue TTM	$6.7M
EBITDA	$-77.1M
Earnings Per Share (EPS)	$-0.43
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-67.81%

How to invest in Arbutus Biopharma Stock (ABUS) from India?

It is very easy for Indian residents to invest directly in Arbutus Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arbutus Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arbutus Biopharma or ABUS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arbutus Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arbutus Biopharma shares which would translate to 0.251 fractional shares of Arbutus Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Arbutus Biopharma, in just a few clicks!

Returns in Arbutus Biopharma (ABUS) for Indian investors in Rupees

The Arbutus Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Arbutus Biopharma investment value today

Current value as on today

₹1,31,605

Returns

₹31,605

(+31.61%)

Returns from Arbutus Biopharma Stock

₹26,642 (+26.64%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Arbutus Biopharma (ABUS)

180%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Arbutus Biopharma Stock from India on INDmoney has increased by 180% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arbutus Biopharma

Morgan Stanley - Brokerage Accounts
11.92%
Whitefort Capital Management, LP.
6.99%
BlackRock Inc
6.83%
Vanguard Group Inc
4.74%
Two Seas Capital LP
4.61%
State Street Corp
2.65%

Analyst Recommendation on Arbutus Biopharma

Buy

81%Buy

18%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Arbutus Biopharma Stock (ABUS)

What analysts predicted

Upside of 47.94%

Target:

$5.13

Current:

$3.47

Insights on Arbutus Biopharma Stock (Ticker Symbol: ABUS)

Price Movement
In the last 1 year, ABUS stock has moved up by 27.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.72M → 1.33M (in $), with an average decrease of 22.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -19.79M → -19.71M (in $), with an average increase of 0.4% per quarter
ABUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 35.3%
ABUS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 27.1%
Price to Sales
ForABUS every $1 of sales, investors are willing to pay $91.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

ABUS Arbutus Biopharma Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$5.9M	↓ 44.86%
Net Income	$-57.1M	↓ 32.35%
Net Profit Margin	-967.8%	↓ 179.01%

	FY19	Y/Y Change
Revenue	$6.0M	↑ 1.88%
Net Income	$-153.7M	↑ 169.22%
Net Profit Margin	-2.6K%	↓ 1589.56%

	FY20	Y/Y Change
Revenue	$6.9M	↑ 15.02%
Net Income	$-65.2M	↓ 57.58%
Net Profit Margin	-943.17%	↑ 1614.19%

	FY21	Y/Y Change
Revenue	$11.0M	↑ 58.92%
Net Income	$-77.4M	↑ 18.62%
Net Profit Margin	-703.96%	↑ 239.21%

	FY22	Y/Y Change
Revenue	$39.0M	↑ 255.11%
Net Income	$-69.5M	↓ 10.21%
Net Profit Margin	-178.01%	↑ 525.95%

	FY23	Y/Y Change
Revenue	$18.1M	↓ 53.51%
Net Income	$-72.8M	↑ 4.89%
Net Profit Margin	-401.57%	↓ 223.56%

	Q2 FY23	Q/Q Change
Revenue	$4.7M	↓ 30.45%
Net Income	$-17.1M	↑ 10.55%
Net Profit Margin	-367.53%	↓ 136.29%

	Q3 FY23	Q/Q Change
Revenue	$4.7M	↑ 0.15%
Net Income	$-20.1M	↑ 17.61%
Net Profit Margin	-431.6%	↓ 64.07%

	Q4 FY23	Q/Q Change
Revenue	$2.1M	↓ 53.95%
Net Income	$-19.3M	↓ 3.94%
Net Profit Margin	-900.33%	↓ 468.73%

	Q1 FY24	Q/Q Change
Revenue	$1.5M	↓ 28.58%
Net Income	$-17.9M	↓ 7.44%
Net Profit Margin	-1.2K%	↓ 266.45%

	Q2 FY24	Q/Q Change
Revenue	$1.7M	↑ 12.66%
Net Income	$-19.8M	↑ 10.75%
Net Profit Margin	-1.1K%	↑ 19.85%

	Q3 FY24	Q/Q Change
Revenue	$1.3M	↓ 22.42%
Net Income	$-19.7M	↓ 0.4%
Net Profit Margin	-1.5K%	↓ 325.59%

	FY18	Y/Y Change
Profit	$-52.0M	↑ 0.0%

	FY19	Y/Y Change
Profit	$-51.6M	↓ 0.79%

	FY20	Y/Y Change
Profit	$-40.6M	↓ 21.37%

	FY21	Y/Y Change
Profit	$9.2M	↓ 122.76%

	FY22	Y/Y Change
Profit	$37.6M	↑ 307.06%

	FY23	Y/Y Change
Profit	$-55.6M	↓ 247.79%

	Q2 FY23	Q/Q Change
Profit	$4.3M	↓ 32.17%

	Q3 FY23	Q/Q Change
Profit	$4.3M	↓ 0.46%

	Q4 FY23	Q/Q Change
Profit	$1.8M	↓ 58.36%

	Q1 FY24	Q/Q Change
Profit	$1.2M	↓ 34.1%

	Q2 FY24	Q/Q Change
Profit	$1.4M	↑ 16.4%

	Q3 FY24	Q/Q Change
Profit	$1.3M	↓ 2.26%

	FY18	Y/Y Change
Operating Cash Flow	$-67.9M	↑ 39.71%
Investing Cash Flow	$-4.1M	↓ 114.83%
Financing Cash Flow	$55.6M	↑ 12.78%

	FY19	Y/Y Change
Operating Cash Flow	$-71.0M	↑ 4.57%
Investing Cash Flow	$28.3M	↓ 786.65%
Financing Cash Flow	$37.5M	↓ 32.63%

	FY20	Y/Y Change
Operating Cash Flow	$-51.4M	↓ 27.55%
Investing Cash Flow	$-14.9M	↓ 152.61%
Financing Cash Flow	$86.7M	↑ 131.59%

	FY21	Y/Y Change
Operating Cash Flow	$-67.5M	↑ 31.28%
Investing Cash Flow	$-12.7M	↓ 14.96%
Financing Cash Flow	$137.2M	↑ 58.2%

	FY22	Y/Y Change
Operating Cash Flow	$-35.4M	↓ 47.65%
Investing Cash Flow	$-74.9M	↑ 491.12%
Financing Cash Flow	$31.8M	↓ 76.82%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 28.36%
Investing Cash Flow	$1.4M	↓ 91.36%
Financing Cash Flow	$4.7M	↓ 76.77%

Arbutus Biopharma Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Arbutus Biopharma (ABUS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arbutus Biopharma Corporation	0.89%	-24.83%	23.72%	19.79%	22.83%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arbutus Biopharma Corporation	NA	NA	0.0	-0.55	-0.68	-0.33	NA	0.56
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arbutus Biopharma Corporation	Buy	$648.1M	22.83%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Organization	Arbutus Biopharma
Employees	73
CEO	Ms. Lindsay Androski J.D., M.B.A.
Industry	Health Technology

Management People of Arbutus Biopharma

Name	Title
Ms. Lindsay Androski J.D., M.B.A.	Interim President, CEO & Director
Mr. David C. Hastings CPA	CFO & Chief Accounting Officer
Ms. Lisa M. Caperelli	Vice President of Investor Relations
Mr. J. Christopher Naftzger BA, Esq., J.D.	General Counsel, Chief Compliance Officer & Secretary
Ms. Shannon Briscoe SPHR	Vice President of Human Resources
Dr. Karen Sims M.D., Ph.D.	Chief Medical Officer
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.	Corporate Secretary

Important FAQs about investing in ABUS Stock from India :

What is Arbutus Biopharma share price today?

Arbutus Biopharma share price today stands at $3.47, Open: $3.39 ; Previous Close: $3.39 ; High: $3.47 ; Low: $3.33 ; 52 Week High: $4.73 ; 52 Week Low: $2.30.

The stock opens at $3.39, after a previous close of $3.39. The stock reached a daily high of $3.47 and a low of $3.33, with a 52-week high of $4.73 and a 52-week low of $2.30.

Can Indians buy Arbutus Biopharma shares?

Yes, Indians can invest in the Arbutus Biopharma (ABUS) from India.

With INDmoney, you can buy Arbutus Biopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Arbutus Biopharma at zero transaction cost.

How can I buy Arbutus Biopharma shares from India?

It is very easy to buy Arbutus Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arbutus Biopharma (ABUS) be purchased?

Yes, you can buy fractional shares of Arbutus Biopharma with INDmoney app.

What are the documents required to start investing in Arbutus Biopharma stocks?

To start investing in Arbutus Biopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.